-
Product Insights
Net Present Value Model: CNMAU-8
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model CNMAU-8 Drug Details CNMAU-8 is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – CNMAU-8
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry CNMAU-8 Drug Details CNMAU-8 is under development for the treatment of relapsing multiple sclerosis,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – RNS-60
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry RNS-60 Drug Details RNS-60 is under development for the treatment of acute ischemic stroke,...